Cancer Cachexia Raises the Plasma Concentration of Oxymorphone Through the Reduction of CYP3A But Not CYP2D6 in Oxycodone-Treated Patients

This study evaluated the plasma concentrations of oxycodone and its demethylates and opioid‐induced adverse effects based on cachexia stage in cancer patients receiving oxycodone. Seventy patients receiving oxycodone for cancer pain were enrolled. Cachexia was evaluated using the Glasgow Prognostic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical pharmacology 2013-08, Vol.53 (8), p.812-818
Hauptverfasser:	Naito, Takafumi, Tashiro, Masaki, Ishida, Takuya, Ohnishi, Kazunori, Kawakami, Junichi
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Analgesics, Opioid - blood Analgesics, Opioid - pharmacokinetics Analgesics, Opioid - therapeutic use Cachexia - blood Cachexia - drug therapy Cachexia - etiology Cancer cancer cachexia CYP2D6 Cytochrome P-450 CYP2D6 - metabolism Cytochrome P-450 CYP3A - metabolism Female Humans Male Middle Aged Morphinans - blood Narcotics Neoplasms - blood Neoplasms - complications Neoplasms - drug therapy oxycodone Oxycodone - blood Oxycodone - pharmacokinetics Oxycodone - therapeutic use oxymorphone Oxymorphone - blood Pain - blood Pain - drug therapy pharmacokinetics Plasma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!